Contrasting Dimension Therapeutics (DMTX) & Corbus Pharmaceuticals Holdings (CRBP)
Dimension Therapeutics (NASDAQ: DMTX) and Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, risk, earnings, profitability, valuation, dividends and institutional ownership.
Risk & Volatility
Dimension Therapeutics has a beta of 2.95, indicating that its stock price is 195% more volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals Holdings has a beta of 2.36, indicating that its stock price is 136% more volatile than the S&P 500.
This is a summary of current ratings and target prices for Dimension Therapeutics and Corbus Pharmaceuticals Holdings, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Corbus Pharmaceuticals Holdings||0||0||4||0||3.00|
Dimension Therapeutics presently has a consensus price target of $5.08, indicating a potential downside of 15.30%. Corbus Pharmaceuticals Holdings has a consensus price target of $19.75, indicating a potential upside of 156.49%. Given Corbus Pharmaceuticals Holdings’ stronger consensus rating and higher probable upside, analysts plainly believe Corbus Pharmaceuticals Holdings is more favorable than Dimension Therapeutics.
This table compares Dimension Therapeutics and Corbus Pharmaceuticals Holdings’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Corbus Pharmaceuticals Holdings||-1,001.77%||-107.10%||-83.38%|
Institutional and Insider Ownership
70.3% of Dimension Therapeutics shares are held by institutional investors. Comparatively, 31.8% of Corbus Pharmaceuticals Holdings shares are held by institutional investors. 2.2% of Dimension Therapeutics shares are held by company insiders. Comparatively, 11.9% of Corbus Pharmaceuticals Holdings shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Dimension Therapeutics and Corbus Pharmaceuticals Holdings’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Dimension Therapeutics||$14.88 million||10.10||-$50.87 million||($2.14)||-2.80|
|Corbus Pharmaceuticals Holdings||$2.76 million||140.11||-$27.54 million||($0.61)||-12.62|
Corbus Pharmaceuticals Holdings has higher revenue, but lower earnings than Dimension Therapeutics. Corbus Pharmaceuticals Holdings is trading at a lower price-to-earnings ratio than Dimension Therapeutics, indicating that it is currently the more affordable of the two stocks.
Corbus Pharmaceuticals Holdings beats Dimension Therapeutics on 7 of the 13 factors compared between the two stocks.
Dimension Therapeutics Company Profile
Dimension Therapeutics, Inc. is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa). The Company’s gene therapy product candidates and programs are designed to provide a functional copy of an abnormal or missing gene using the advanced adeno-associated virus (AAV)-based vector delivery technology. DTX101 is the Company’s lead gene therapy product candidate designed to deliver Factor IX (FIX), gene expression in patients with hemophilia B. DTX201 is its Factor VIII (FVIII) gene therapy program for the treatment of hemophilia A. DTX301 is its gene therapy product candidate designed for the treatment of patients with OTC deficiency. DTX401 is its gene therapy program for the treatment of patients with GSDIa.
Corbus Pharmaceuticals Holdings Company Profile
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company’s product, anabasum is a synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. Anabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing anabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).
Receive News & Stock Ratings for Dimension Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc. and related stocks with our FREE daily email newsletter.